C2n Diagnostics LLC has received a $20 million investment in its Alzheimer’s blood test, APTUS-Aβ, from the philanthropy group GHR Foundation. The test measures various types of amyloid beta in the blood and then factors in additional data, such as age, to develop a probability score for amyloid-related pathology in the brain.
Keeping you up to date on recent developments in neurology, including: Study finds tDCS does not affect metabolism; AI successfully used to identify different types of brain injuries; Dynamic stimulation of the visual cortex allows blind and sighted people to 'see' shapes.
The FDA granted Setpoint Medical Corp. an investigational device exemption (IDE) approval to study its bioelectronic platform in rheumatoid arthritis (RA) patients. The Valencia, Calif.-based company expects to begin enrollment in a multicenter, double-blind, randomized, sham-controlled pivotal trial in patients with RA in the third quarter of 2020, Setpoint President and CEO Murthy Simhambhatla told BioWorld.
Palo Alto, Calif.-based Limbix Health Inc. secured $9 million in series A funding for development of Spark, its prescription digital therapeutic (PDT) designed to treat depression in adolescents. GSR Ventures led the round with additional funding from other existing investors, including Sequoia Capital, Storm Ventures, Nextgen Venture Partners and Bixink Therapeutics.
Keeping you up to date on recent developments in neurology, including: Focused ultrasound opens brain for gene therapy; Study links early sleep problems to autism diagnosis; New trial platform could accelerate finding a cure for Parkinson's disease.
Digital therapeutics have had a tough time gaining traction in the last few years. They’ve been hampered by sometimes reluctant payers, providers and regulators who lack familiarity with the approach, which typically employs an app or other technology to treat a patient by supporting behavioral adjustments.
Keeping you up to date on recent developments in neurology, including: Light-based stimulation relieves symptoms of Parkinson's, Implant-free optogenetics minimizes brain damage during neuronal stimulation, Persistent and worsening insomnia may predict persistent depression in older adults.
PARIS – Braintale SAS, of Paris, has gained CE mark approval for Brainquant. This software platform, which uses DICOM radiology imaging, enables diffusion MRI scans to be processed as part of managing patients in a coma following brain injury.
Keeping you up to date on recent developments in neurology, including: Nanocarrier developed for drug delivery across the BBB; 3D face analysis could screen for sleep apnea; Long noncoding RNA has sex-specific role in depression; Noncoding TET2 variants affect neurodegeneration risk.
The largest study to date on hypermutated gliomas has delivered new insights into their origin, as well as their response to several different treatments. Specifically, even though they are hypermutated, such tumors are unlikely to respond to PD-1 blockers.
RSS
